Kymera Therapeutics (KYMR) Return on Sales (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Return on Sales data on file, last reported at 0.14% in Q1 2026.

• On a quarterly basis, Return on Sales fell 6.0% year-over-year to 0.14% in Q1 2026; TTM through Mar 2026 was 0.22%, a 12.0% decrease from a year earlier, with the FY2025 full-year figure at 0.19%, down 9.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.14%, up from 0.34% in the prior quarter.
• Over the last five years, Return on Sales for KYMR reached as high as 0.02% in Q4 2022 and fell as low as 1.24% in Q3 2025.
• Historically, Return on Sales has averaged 0.23% across 5 years, with a median of 0.12% in 2023.
• On a YoY basis, Return on Sales climbed as much as 9 bps in 2025 and fell as far as 65 bps in 2025.
• Year by year, Return on Sales stood at 0.02% in 2022, then plunged by 58 bps to 0.04% in 2023, then tumbled by 188 bps to 0.11% in 2024, then plunged by 212 bps to 0.34% in 2025, then soared by 58 bps to 0.14% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.14% in Q1 2026, 0.34% in Q4 2025, and 1.24% in Q3 2025.